NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
NeuroPace (Nasdaq: NPCE) announced that the Centers for Medicare & Medicaid Services (CMS) has maintained the current Medicare Severity Diagnosis Related Group (MS-DRG) assignment for RNS® System procedures under MS-DRG 023 for FY 2026. This decision comes after CMS initially proposed reassigning epilepsy with neurostimulator cases to MS-DRG 020-022.
CEO Joel Becker welcomed the decision, highlighting its importance for hospitals providing RNS System treatment to Medicare beneficiaries. The company will continue collaborating with CMS on MS-DRG improvements and reimbursement policies to ensure broader access to their epilepsy treatment technology.
NeuroPace (Nasdaq: NPCE) ha annunciato che i Centers for Medicare & Medicaid Services (CMS) hanno confermato l'attuale classificazione Medicare Severity Diagnosis Related Group (MS-DRG) per le procedure con il sistema RNS® sotto il codice MS-DRG 023 per l'anno fiscale 2026. Questa decisione segue una proposta iniziale del CMS di riassegnare i casi di epilessia trattati con neurostimolatore ai codici MS-DRG 020-022.
Il CEO Joel Becker ha accolto favorevolmente la decisione, sottolineandone l'importanza per gli ospedali che offrono il trattamento con il sistema RNS ai beneficiari Medicare. L'azienda continuerà a collaborare con il CMS per migliorare i codici MS-DRG e le politiche di rimborso, al fine di garantire un accesso più ampio alla loro tecnologia per il trattamento dell'epilessia.
NeuroPace (Nasdaq: NPCE) anunció que los Centers for Medicare & Medicaid Services (CMS) han mantenido la asignación actual del Medicare Severity Diagnosis Related Group (MS-DRG) para los procedimientos con el sistema RNS® bajo el código MS-DRG 023 para el año fiscal 2026. Esta decisión se da después de que CMS propusiera inicialmente reasignar los casos de epilepsia tratados con neuroestimulador a los códigos MS-DRG 020-022.
El CEO Joel Becker celebró la decisión, destacando su importancia para los hospitales que brindan tratamiento con el sistema RNS a beneficiarios de Medicare. La compañía continuará colaborando con CMS para mejorar los códigos MS-DRG y las políticas de reembolso, asegurando un acceso más amplio a su tecnología para el tratamiento de la epilepsia.
NeuroPace (나스닥: NPCE)는 Medicare 및 Medicaid 서비스 센터(CMS)가 2026 회계연도에 RNS® 시스템 절차에 대한 현재의 Medicare Severity Diagnosis Related Group(MS-DRG) 분류를 MS-DRG 023으로 유지하기로 했다고 발표했습니다. 이 결정은 CMS가 처음에 신경자극기를 사용하는 간질 사례를 MS-DRG 020-022로 재분류할 것을 제안한 후 나온 것입니다.
CEO 조엘 베커는 이 결정을 환영하며, Medicare 수혜자에게 RNS 시스템 치료를 제공하는 병원에 중요한 의미가 있다고 강조했습니다. 회사는 MS-DRG 개선 및 상환 정책에 대해 CMS와 지속적으로 협력하여 간질 치료 기술에 대한 더 넓은 접근을 보장할 것입니다.
NeuroPace (Nasdaq : NPCE) a annoncé que les Centers for Medicare & Medicaid Services (CMS) ont maintenu l'affectation actuelle du groupe de diagnostic lié à la gravité de Medicare (MS-DRG) pour les procédures du système RNS® sous le code MS-DRG 023 pour l'exercice 2026. Cette décision fait suite à une proposition initiale de CMS de reclasser les cas d'épilepsie traités par neurostimulateur dans les codes MS-DRG 020-022.
Le PDG Joel Becker a salué cette décision, soulignant son importance pour les hôpitaux fournissant le traitement par système RNS aux bénéficiaires de Medicare. L'entreprise continuera de collaborer avec CMS pour améliorer les codes MS-DRG et les politiques de remboursement afin d'assurer un accès plus large à leur technologie de traitement de l'épilepsie.
NeuroPace (Nasdaq: NPCE) gab bekannt, dass die Centers for Medicare & Medicaid Services (CMS) die aktuelle Zuordnung der Medicare Severity Diagnosis Related Group (MS-DRG) für RNS®-System-Prozeduren unter MS-DRG 023 für das Geschäftsjahr 2026 beibehalten haben. Diese Entscheidung folgt auf einen ursprünglichen Vorschlag von CMS, Epilepsiefälle mit Neurostimulator den MS-DRG 020-022 zuzuordnen.
CEO Joel Becker begrüßte die Entscheidung und betonte deren Bedeutung für Krankenhäuser, die RNS-Systembehandlungen für Medicare-Begünstigte anbieten. Das Unternehmen wird weiterhin mit CMS an Verbesserungen der MS-DRG und Erstattungsrichtlinien zusammenarbeiten, um einen breiteren Zugang zu ihrer Epilepsiebehandlungstechnologie zu gewährleisten.
- Maintenance of current MS-DRG assignment ensures reimbursement stability
- Continued access to RNS System for Medicare beneficiaries
- Positive regulatory relationship with CMS demonstrated through successful feedback process
- None.
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule.
“We appreciate CMS’ openness to public comment on the proposed rule and its reconsideration of the original proposal to reassign RNS cases to MS-DRG 020-022. We commend CMS’ decision to maintain the current MS-DRG assignment for RNS® System procedures under MS-DRG 023,” said Joel Becker, Chief Executive Officer of NeuroPace. “This maintains continuity for hospitals providing the RNS System to Medicare beneficiaries, who represent a vulnerable and underserved epilepsy population.”
NeuroPace will continue to work with CMS on MS-DRG improvements and other reimbursement related topics. The company remains committed to ensuring that reimbursement policy keeps pace with clinical innovation and that access to the RNS System is available for all who may benefit.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: the outcomes of NeuroPace’s continued work with CMS on Medicare reimbursement for the RNS System. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 13, 2025, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
Investor Contact:
Scott Schaper
Head of Investor Relations
sschaper@neuropace.com
investors@neuropace.com
FAQ
What did CMS decide regarding NeuroPace's RNS System reimbursement for FY 2026?
How does the CMS decision affect NPCE's Medicare patients?
What was NeuroPace's response to the CMS reimbursement decision?
What is the significance of MS-DRG classification for NPCE's business?
